Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03539744
What this trial is testing

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Multiple Myeloma
AbbVie 265
Testing effectiveness (Phase 2)Study completedNCT04083534
What this trial is testing

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Regeneron Pharmaceuticals 43
Testing effectiveness (Phase 2)WithdrawnNCT02756663
What this trial is testing

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07695740
What this trial is testing

Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Excyte Biopharma Ltd 64
Testing effectiveness (Phase 2)Study completedNCT04191616
What this trial is testing

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 54
Early research (Phase 1)Study completedNCT00592046
What this trial is testing

A Phase I Trial of ZIO-101 in Hematologic Cancers

Who this might be right for
Acute LeukemiaChronic Myeloproliferative DiseaseChronic Lymphoproliferative Disease+3 more
Alaunos Therapeutics 12
Early research (Phase 1)Study completedNCT05011097
What this trial is testing

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Wuhan YZY Biopharma Co., Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT02046070
What this trial is testing

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 148
Large-scale testing (Phase 3)Study completedNCT04939142
What this trial is testing

Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Antengene Corporation 154
Testing effectiveness (Phase 2)Looking for participantsNCT07312188
What this trial is testing

F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD 90
Early research (Phase 1)Ended earlyNCT04887259
What this trial is testing

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Who this might be right for
Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myeloid Leukemia
Lava Therapeutics 16
Testing effectiveness (Phase 2)Ended earlyNCT00281879
What this trial is testing

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
OHSU Knight Cancer Institute 200
Early research (Phase 1)Study completedNCT03829020
What this trial is testing

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 9
Early research (Phase 1)WithdrawnNCT02658396
What this trial is testing

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma
Dana-Farber Cancer Institute
Not applicableStudy completedNCT05217082
What this trial is testing

A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 35
Early research (Phase 1)Looking for participantsNCT06644118
What this trial is testing

OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Zhejiang University 58
Early research (Phase 1)Study completedNCT00310024
What this trial is testing

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
National Cancer Institute (NCI) 40
Early research (Phase 1)UnknownNCT01199718
What this trial is testing

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Cylene Pharmaceuticals 22
Early research (Phase 1)Ended earlyNCT06588660
What this trial is testing

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 1
Not applicableApproved For MarketingNCT02477891
What this trial is testing

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC
Next Page